Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.

Autor: Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Kaku Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Hinay AA Jr; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Guo Z; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Kihara M; Wakaba Clinic, Kanagawa, Japan., Saito F; Namikibashi Clinic, Tokyo, Japan., Uwamino Y; Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan., Kuramochi J; Interpark Kuramochi Clinic, Utsunomiya, Japan; Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan., Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan. Electronic address: keisato@g.ecc.u-tokyo.ac.jp.
Jazyk: angličtina
Zdroj: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Mar; Vol. 24 (3), pp. e147-e148. Date of Electronic Publication: 2024 Jan 08.
DOI: 10.1016/S1473-3099(23)00784-3
Abstrakt: Competing Interests: This work was supported in part by the Japan Agency for Medical Research and Development (AMED) Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA programme (JP223fa627001 to KSa), AMED SCARDA Program on R&D of New Generation Vaccine Including New Modality Application (JP223fa727002 to KSa); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146 to KSa; JP21fk0108494 to G2P-Japan Consortium and KSa; JP21fk0108425 to KSa; JP21fk0108432 to KSa; JP22fk0108511 to G2P-Japan Consortium and KSa; JP22fk0108516 to KSa; JP22fk0108506 to KSa; JP22fk0108534 to KSa); AMED Research Program on HIV/AIDS (JP22fk0410039 to KSa); Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST; JPMJCR20H4 to KSa); Japan Society for the Promotion of Science (JSPS) KAKENHI Fund for the Promotion of Joint International Research (International Leading Research) (JP23K20041 to G2P-Japan and KSa); JSPS Core-to-Core Program (A Advanced Research Networks; JPJSCCA20190008 to KSa); JSPS Research Fellow DC2 (22J11578 to KU); JSPS Research Fellow DC1 (23KJ0710 to YKo); The Tokyo Biochemical Research Foundation (to KSa); and The Mitsubishi Foundation (to KSa). KSa has received consulting fees from Moderna Japan and Takeda Pharmaceutical and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. All other authors declare no competing interests. Members of The Genotype to Phenotype Japan (G2P-Japan) Consortium are listed in the appendix (p 9).
Databáze: MEDLINE